The total operating performance of the “BioIndustrial” segment increased by 23 percent to Euro 3.5m in the first quarter of 2015/16, from Euro 2.9m in the previous year period. The enzyme business of the WeissBioTech subsidiary made a significant contribution to this marked increase in revenues. As a result, the share of total Group operating performance of the industrial product business, combined in the “BioIndustrial” segment, increased from 45 percent to 50 percent. The remaining 50 percent were contributed by the “BioScience” segment, representing the collaboration business of BRAIN, where the total operating performance in the first quarter of 2015/16 equally amounted to Euro 3.5m, after a slight increase year-over-year.
The Group operating result (EBIT) declined from Euro -0.5m to Euro -2.1m over the previous year. Adjusted for one-off costs incurred by the initial public offering of BRAIN AG of Euro 0.8m and personnel expenses resulting from a share-based employee compensation scheme of Euro 0.4m, the adjusted Group EBIT amounted to Euro -0.9m in the first three months of fiscal year 2015/16. Thereof, Euro -0.2m relate to the “BioIndustrial” segment and Euro -0.7m to the “BioScience” segment.
“During all meetings with investors in the run-up to the IPO we set great store by detailing our industrialisation strategy. We will press ahead vigorously with advancing our own product pipeline, which first and foremost benefits our “BioIndustrial” segment. The first quarter figures of the 2015/2016 fiscal year clearly illustrate that we can grow this segment without compromising our successful collaboration business with industrial partners,” says Dr Jürgen Eck, CEO of BRAIN AG.
Key financials (first three months of fiscal year 2015/16)
(in Euro million)1
|Total operating performance2
|Adjustments (consolidation effects)
|Result per share in Euro
|Number of shares
||Cash flows from operating activities
||Cash flows from investing activities
||Cash flows from financing activities
- The financial figures of fiscal 2015/16 are comparable only to a limited extent to the values of the previous year, as for the first quarter of FY 2014/15 they only include the financial figures of the WeissBioTech organisations for the months of November and December 2014 due to the acquisition.
- Revenues + change in inventories + other income including R&D grants, only comparable to a limited extent
- Adjusted for one-off costs of the IPO and expenses resulting from share-based employee participation plans
More detailed information on the quarterly financial results and the related consolidated financial tables (profit and loss statement, balance sheet, cash flow statement) are available at www.brain-biotech.de/en/investor-relations/financial-publications as part of the interim statement for the three months period ending December 31, 2015.